IRONWOOD PHARMACEUTICALS INC Logo

IRONWOOD PHARMACEUTICALS INC

Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.

IRWD | US

Overview

Corporate Details

ISIN(s):
US46333X1081
LEI:
Country:
United States of America
Address:
100 SUMMER STREET, SUITE 2300, 2110 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ironwood Pharmaceuticals Inc. is a gastrointestinal (GI) healthcare company focused on advancing the treatment of GI diseases. As a commercial-stage biotechnology firm, its core activities involve the research, development, and commercialization of innovative therapies for patients with digestive disorders. The company maintains a singular focus on the GI field, leveraging specialized expertise to address unmet medical needs and redefine the standard of care. Its primary commercial product is LINZESS® (linaclotide), a leading prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IRONWOOD PHARMACEUTICALS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IRONWOOD PHARMACEUTICALS INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IRONWOOD PHARMACEUTICALS INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.
United States of America LBRX
Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel LCTX
Lineage Cell Therapeutics, Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
United States of America LCTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.